Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Deyo, D. Cherkin, D. Cherkin, M. Ciol (1992)
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.Journal of clinical epidemiology, 45 6
L Blais, O Sheehy, JM St-Hilaire, G Bernier, P Godfroid, JJ LeLorier (2005)
Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy [published correction appears in Pharmacoeconomics. 2005;23(9):944]., 23
M. Brodie, J. French (2000)
Management of epilepsy in adolescents and adultsThe Lancet, 356
Jennifer Nicholas, L. Ridsdale, M. Richardson, M. Ashworth, M. Gulliford (2012)
Trends in antiepileptic drug utilisation in UK primary care 1993–2008: Cohort study using the General Practice Research DatabaseSeizure, 21
E. Louis (2009)
Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects.Current Neuropharmacology, 7
R. Mattson, J. Cramer, J. Collins (1992)
A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group.The New England journal of medicine, 327 11
M. Brodie, G. Sills (2011)
Combining antiepileptic drugs—Rational polytherapy?Seizure, 20
A. Malerba, C. Ciampa, S. Fazio, C. Fattore, B. Frassine, A. Neve, Simona Pellacani, L. Specchio, A. Tiberti, P. Tinuper, E. Perucca (2010)
Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in ItalyEpilepsy Research, 91
D. Buck, A. Jacoby, G. Baker, D. Chadwick (1997)
Factors influencing compliance with antiepileptic drug regimesSeizure, 6
R. Mattson, J. Cramer, J. Collins, D. Smith, A. Delgado-Escueta, T. Browne, P. Williamson, D. Treiman, J. McNamara, C. McCutchen (1985)
Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.The New England journal of medicine, 313 3
J. Cramer, S. Mintzer, J. Wheless, R. Mattson (2010)
Adverse effects of antiepileptic drugs: a brief overview of important issuesExpert Review of Neurotherapeutics, 10
P. Knoester, A. Boendermaker, Antoine Egberts, Yechiel Hekster, Antoine Keyser, Johan Severens, Willy Renier, C. Deckers (2005)
Cost-effectiveness of add-on lamotrigine therapy in clinical practiceEpilepsy Research, 67
J. Farley, C. Harley, Joshua Devine (2006)
A comparison of comorbidity measurements to predict healthcare expenditures.The American journal of managed care, 12 2
W. Hauser, W. Hauser, J. Annegers, J. Annegers, W. Rocca (1996)
Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota.Mayo Clinic proceedings, 71 6
L. Blais, O. Sheehy, J. Saint‐Hilaire, G. Bernier, Philippe Godfroid, J. LeLorier (2012)
Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsyPharmacoEconomics, 23
Jong Lee, B. Dworetzky (2010)
Rational Polytherapy with Antiepileptic DrugsPharmaceuticals, 3
ImportanceTo our knowledge, the current study is the first to describe antiepileptic drug (AED) combination therapy patterns according to their mechanism of action (MOA) in a real-world setting and to evaluate the differences in outcomes comparing different-MOA combination therapy with same-MOA combination therapy for patients with partial-onset seizure. ObjectiveTo compare treatment persistence and health care use with AED combinations categorized by MOA in patients with partial-onset seizures. Design, Setting, and ParticipantsUsing the Truven Health MarketScan Commercial Claims Database containing 96 million covered lives from July 1, 2004, through March 31, 2011, adults with concomitant use of 2 different AEDs and a recent partial-onset seizure diagnosis were selected. Antiepileptic drugs were categorized by MOA: sodium channel blockers (SC), gamma-aminobutyric acid analogs (G), synaptic vesicle protein 2A binding (SV2), and multiple mechanisms (M). Patients were assigned a combination category based on their concomitant AED use. Main Outcomes and MeasuresTreatment persistence was measured from the start of AED combination therapy until the end of the combination. Health care resource use was measured during the combination treatment duration. Multivariate analyses evaluated AED discontinuation risk and health care use according to MOA combinations. ResultsDistribution of 8615 selected patients by combination was 3.3% for G+G, 7.5% for G+SV2, 8.6% for G+M, 13.9% for SC+SC, 19.0% for G+SC, 21.5% for SC+M, and 26.3% for SC+SV2. The same-MOA (G+G and SC+SC) combinations had the shortest persistence (mean [SD], 344 [345] days and 513 [530] days, respectively) and greater hazard of discontinuation compared with different-MOA combinations. Patients with different-MOA G combinations had a significantly lower risk for inpatient admission (odds ratio, 0.716; 95% CI, 0.539-0.952; P = .02) compared with G+G combinations. Patients with different-MOA SC combinations had significantly lower risks for emergency department visits (odds ratio, 0.853; 95% CI, 0.742-0.980; P = .03) compared with SC+SC combinations. Conclusions and RelevanceThe findings suggest that AED combinations with different MOAs have greater effectiveness as measured by treatment persistence and lower risks for hospitalization and emergency department visits. Further research is needed to more fully understand the role of the MOA in achieving optimal outcomes.
JAMA Neurology – American Medical Association
Published: Aug 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.